

**Mississippi Division Of Medicaid**  
**Preferred Drug List Changes**  
**P&T Meeting Date: October 18, 2016**  
**PDL Changes Effective Date: January 1, 2017**



The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2017, pending recommendation and/or approval by the P&T Committee, DOM, and DOM's Executive Director.

For a comprehensive PDL, refer to <http://www.medicaid.ms.gov/providers/pharmacy/preferred-drug-list/>.

<b>NEW PREFERRED DRUGS</b>	
<b>THERAPEUTIC CLASS</b>	<b>RECOMMENDED for PREFERRED STATUS</b>
ANGIOTENSIN MODULATORS	valsartan
ANGIOTENSIN MODULATORS	valsartan/amlodipine
ANGIOTENSIN MODULATORS	valsartan/amlodipine/HCTZ
ANTICOAGULANTS	ELIQUIS (apixaban)
ANTICOAGULANTS	enoxaparin
ANTICOAGULANTS	PRADAXA (dabigatran)
ANTICOAGULANTS	XARELTO 15mg and 20mg (rivaroxaban)
ANTICONVULSANTS	levetiracetam ER
ANTIMIGRAINE AGENTS, TRIPTAN	sumatriptan nasal spray
ANTIMIGRAINE AGENTS, TRIPTAN	sumatriptan injectable
ANTIPARASITICS (TOPICAL)	SKLICE (ivermectin)
ANTIRETROVIRALS	DESCOVY (emtricitabine/tenofovir alafenam)
COLONY STIMULATING FACTORS	GRANIX (tbo-filgrastim)
COLONY STIMULATING FACTORS	NEUPOGEN Vial (filgrastim)
COLONY STIMULATING FACTORS	ZARXIO (filgrastim)
GLUCOCORTICOIDS (INHALED)	ADVAIR Diskus (fluticasone/salmeterol)
HEPATITIS C TREATMENTS	VIEKIRA XR (ombitasvir/paritaprevir/ritonavir)
HYPERURICEMIA & GOUT	MITIGARE (colchicine)
HYPOGLYCEMICS, DPP4S AND COMBINATIONS	JENTADUETO XR (linagliptin/metformin)
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	VICTOZA (liraglutide)
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER INHIBITORS	JARDIANCE (empagliflozin)
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER INHIBITORS	SYNJARDY (empagliflozin/meformin)
MISCELLANEOUS BRAND/GENERIC	epinephrine autoinject pens
OPHTHALMIC ANTI-INFLAMMATORIES	DUREZOL (difluprednate)
OPHTHALMIC ANTI-INFLAMMATORIES	ketorolac
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	olopatadine
OTIC ANTIBIOTICS	ciprofloxacin
PLATELET AGGREGATION INHIBITORS	BRILINTA (ticagrelor)
PLATELET AGGREGATION INHIBITORS	EFFIENT (prasugrel)
STIMULANTS AND RELATED AGENTS	ADZENYS XT ODT (amphetamine)
STIMULANTS AND RELATED AGENTS	amphetamine salt combination ER
STIMULANTS AND RELATED AGENTS	guanfacine ER
STIMULANTS AND RELATED AGENTS	methylphenidate ER (generic Concerta; labelers 00591, 62175 & 68084))

**Mississippi Division Of Medicaid  
Preferred Drug List Changes  
P&T Meeting Date: October 18, 2016  
PDL Changes Effective Date: January 1, 2017**



**NEW NON-PREFERRED DRUGS**

<b>THERAPEUTIC CLASS</b>	<b>RECOMMENDED for NON-PREFERRED STATUS</b>
ANALGESICS, NARCOTIC – LONG ACTING	XTAMPZA (oxycodone myristate)
ANDROGENIC AGENTS	TESTIM (testosterone gel)
ANGIOTENSIN MODULATORS	BYVALSON (nebivolol/valsartan)
ANGIOTENSIN MODULATORS	DIOVAN (valsartan)
ANGIOTENSIN MODULATORS	EXFORGE (valsartan/amlodipine)
ANGIOTENSIN MODULATORS	EXFORGE HCT (valsartan/amlodipine/HCTZ)
ANGIOTENSIN MODULATORS	QBRELIS (lisinopril)
ANTICOAGULANTS	LOVENOX (enoxaparin) Prefilled Syringe
ANTICONVULSANTS	BRIVIACT (brivaracetam)
<b>ANTICONVULSANTS</b>	<b>CARBATROL (carbamazepine)</b>
<b>ANTICONVULSANTS</b>	<b>FYCOMPA (perampanel)</b>
ANTICONVULSANTS	lamotrigine ODT
ANTICONVULSANTS	SPRITAM (levetiracetam)
<b>ANTICONVULSANTS</b>	<b>TEGRETOL XR (carbamazepine)</b>
ANTICONVULSANTS	TOPAMAX Sprinkle (topiramate)
ANTIMIGRAINE AGENTS, TRIPTAN	IMITREX (sumatriptan) injectable
ANTIMIGRAINE AGENTS, TRIPTAN	IMITREX (sumatriptan) nasal spray
ANTIMIGRAINE AGENTS, TRIPTAN	ZEMBRANCE (sumatriptan)
ANTINEOPLASTICS-SELECTED SYSTEMIC ENZYME INHIBITORS	CABOMETYX (cabozantinib s-malate)
ANTIPSYCHOTICS	ABILIFY (aripiprazole)
ANTIPSYCHOTICS	ADASUVE (loxapine)
ANTIPSYCHOITCS	aripiprazole ODT
ANTIPSYCHOTICS	clozapine ODT
ANTIPSYCHOTICS	NUPLAZID (pimavanserin)
ANTIPSYCHOTICS	VRAYLAR (cariprazine)
<b>ANTIRETROVIRALS</b>	<b>COMPLERA (emtricitabine/rilpivirine/tenofovir)</b>
ANTIRETROVIRALS	ODEFSEY (emtricitabine/rilpivirine/tenofovir AF)
BILE SALTS	CHOLBAM (cholic acid)
BILE SALTS	OCALIVA (obeticholic acid)
BRONCHODILATORS & COPD AGENTS	BEVESPI (glycopyrrolate/formoterol)
CYTOKINE & CAM ANTAGONISTS	TALTZ (ixekizumab)
CYTOKINE & CAM ANTAGONISTS	XELJANZ XR (tofacitinib)
GENITAL WARTS & ACTINIC KERATOSIS AGENTS	TOLAK (fluorouracil)
HYPERURICEMIA & GOUT	colchicine
<b>HYPOGLYCEMICS, DPP4S AND COMBINATIONS</b>	<b>KOMBIGLYZE XR (saxagliptin/metformin)</b>
<b>HYPOGLYCEMICS, DPP4S AND COMBINATIONS</b>	<b>ONGLYZA (saxagliptin)</b>
<b>HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS</b>	<b>TANZEUM (albiglutide)</b>
IRRITABLE BOWEL SYNDROME/SHORT BOWEL SYNDROM AGENTS/SELECTED GI AGENTS	VIBERZI (eluxadoline)
MULTIPLE SCLEROSIS AGENTS	ZINBRYTA (daclizumab)

**Mississippi Division Of Medicaid  
 Preferred Drug List Changes  
 P&T Meeting Date: October 18, 2016  
 PDL Changes Effective Date: January 1, 2017**



<b>NEW NON-PREFERRED DRUGS</b>	
<b>THERAPEUTIC CLASS</b>	<b>RECOMMENDED for NON-PREFERRED STATUS</b>
OPHTHALMIC ANTIBIOTICS	CILOXAN Solution (ciprofloxacin)
OPHTHALMIC ANTIBIOTICS	levofloxacin
OPHTHALMIC ANTIBIOTICS	MOXEZA (moxifloxacin)
OPHTHALMIC ANTIBIOTICS	neomycin/polymyxin/gramicidin
OPHTHALMIC ANTIBIOTICS	neomycin/polymyxin/hydrocortisone
OPHTHALMIC ANTIBIOTICS	ofloxacin
OPHTHALMIC ANTIBIOTICS	sulfacetamide
OPHTHALMIC ANTIBIOTICS	TOBRADEX ST SUSPENSION (tobramycin/dexamethasone)
OPHTHALMIC ANTIBIOTICS	TOBREX (tobramycin)
OPHTHALMIC ANTI-INFLAMMATORIES	XIIDRA (lifitegrast)
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	PATADAY (olopatadine)
OTIC ANTIBIOTICS	ofloxacin
OTIC ANTIBIOTICS	OTOVEL (ciprofloxacin/fluocinolone)
PLATELET AGGREGATION INHIBITORS	ZONTIVITY (vorapaxar)
STEROIDS (TOPICAL)	SERNIVO (betamethasone dipropionate)
STIMULANTS AND RELATED AGENTS	ADDERALL XR (amphetamine salt combination)
STIMULANTS AND RELATED AGENTS	dexmethylphenidate ER
STIMULANTS AND RELATED AGENTS	dextroamphetamine IR
STIMULANTS AND RELATED AGENTS	methylphenidate CD (generic Metadate CD)
STIMULANTS AND RELATED AGENTS	methylphenidate ER Caps (generic Ritalin LA)
STIMULANTS AND RELATED AGENTS	methylphenidate ER Tabs (generic Ritalin SR)
ULCERATIVE COLITIS AND CROHN'S AGENTS	DIPENTUM (olsalazine)
ULCERATIVE COLITIS AND CROHN'S AGENTS	mesalamine tablet

Mississippi Division Of Medicaid  
 Preferred Drug List Changes  
 P&T Meeting Date: October 18, 2016  
 PDL Changes Effective Date: January 1, 2017



NEW THERAPEUTIC CLASSES/DRUGS	
NEW THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
HEREDITARY ANGIOEDEMA	BERINERT (C1 esterase inhibitor)

NEW THERAPEUTIC CLASSES/DRUGS	
NEW THERAPEUTIC CLASS	RECOMMENDED for Non-PREFERRED STATUS
HEREDITARY ANGIOEDEMA	<i>CINRYZE VIAL (C1 esterase inhibitor)</i>
HEREDITARY ANGIOEDEMA	<i>FIRAZYR SYRINGE (icatibant acetate)</i>
HEREDITARY ANGIOEDEMA	<i>KALBITOR VIAL (ecallantide)</i>
HEREDITARY ANGIOEDEMA	<i>RUCONEST VIAL (C1 esterase inhibitor, recombinant)</i>

*Existing users as of December 31, 2016 will be grandfathered.*